Passage Bio Stock (NASDAQ:PASG), Trade Ideas

Passage Bio

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

News

Penny Stocks

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ATAK

DUNE

EGIO

GMBL

ICCT

MESO

MGAM

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NOGN

PASG

PETV

PRZO

SXTP

VINO

Shares of  BlackBerry Limited  (NYSE: BB) moved lower in pre-market trading following the release of third-quarter results.

Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket

Health Care

General

Passage Bio Inc (NASDAQ: PASG) announced initial safety and biomarker data from three Cohort 1 patients in the ongoing global Phase 1/2 upliFT-D clinical trial evaluating PBFT02, an adeno-associated virus (AAV)-delivery gene therapy for frontotemporal dementia (FTD) with 

Neurology-Focused Passage Bio Reveals Initial Data From Dementia Study, Outlines Strategic Priorities

Price Target

Analyst Ratings

AZPN

BNTX

CARA

MNDY

SGRY

SKIN

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Monday.Com To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday

Passage Bio Inc

California cannabis producer Blüm Holdings Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/BLMH#OTCQB">BLMH</a>) announced on Tuesday financial results for the full year and fourth quarter ended Dec. 31, 2023.
The company reported a 36% year-over-year drop in revenue to $33.2 million, due to a "strategic slowdown in its underperforming distribution segment." However, the company's CFO Patty Chan said the decrease in gross margin was only $0.5 million on a revenue decrease of $18.8 million.
"2023 was a truly transformative year for Blüm Holdings during which the Company focused on disposing nearly all the company's underperforming assets and significantly reducing selling, general, and administrative expenses while simultaneously realigning our strategic focus to increasing our gross margin from 35% in 2022 to 53% in 2023," Chan said.&nbsp;
During the fourth quarter the company completed the exit of its unprofitable cultivation facility in Northern California.
Subsequent to the quarter, Blüm Holdings, Inc. became a parent company of Unrivaled Brands, Inc. In January, Unrivaled Brands, said it had wrapped up its <a href="https://www.benzinga.com/markets/cannabis/23/10/35189295/another-cannabis-company-opts-for-reorganization-heres-what-investors-need-to-know">previously announced</a> strategic<a href="https://www.benzinga.com/markets/cannabis/24/01/36652645/california-weed-co-wraps-up-strategic-reorganization-this-is-unrivaleds-new-name"> reorganization</a>.
As another earnings season wraps up, the financial performance of top cannabis operators nationwide will surely be one of the hot topics at this week's <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a> in Florida.
<figure class="wp-block-image aligncenter size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/16084410/2231044_CCCFloridaGIF_V2_031124-1-38.gif" alt="" class="wp-image-293822" /></a></figure>
<h3 class="wp-block-heading">Q4 2023 Financial Highlights</h3>
<ul>
<li>Revenues remained steady at $8.1 million, with gross margin increasing to 54% from 51% in the prior quarter ended Sept. 30, 2023.</li>
<li>Gross profit totaled $4.4 million, compared to $4.2 million in the prior quarter.</li>
<li>Operating expenses increased by 23% to $11.1 million compared to the consecutive prior quarter.</li>
<li>Net loss from continuing operations was $9.6 million, an increase from $3.1 million in the fiscal third quarter.</li>
</ul>
<h3 class="wp-block-heading">FY 2023 Financial Highlights</h3>
<ul>
<li>Gross profit was $17.7 million, down from $18.1 million in 2022.</li>
<li>Net loss from continuing operations was $13.8 million, an improvement of 93% compared to $183.9 million from the prior year.</li>
<li>Adjusted EBITDA loss from continuing operations, a non-GAAP measure was $6 million, compared to adjusted EBITDA loss of 18.3 million in the prior year.</li>
<li>Cash used in operating activities from continuing operations decreased 85% to $1 million compared to $6.4 million in the prior year.</li>
</ul>
<h3 class="wp-block-heading">BLMH Price Action</h3>
Blüm Holdings' shares traded 12.36% lower at $0.78 per share after the market close on Monday.

Cannabis

Earnings

BLMH

California Cannabis Co. Blüm Reports 36% YoY Drop In 2023 Revenue, Narrows Net Loss By 93%

Oppenheimer analyst Kristen Owen maintains Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) with a Outperform and raises the price target from $62 to $67.

CTVA

Oppenheimer Maintains Outperform on Corteva, Raises Price Target to $67

Charles Schwab Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/schw#NYSE">SCHW</a>) reported better-than-expected first-quarter <a href="https://www.benzinga.com/news/earnings/24/04/38252489/charles-schwab-reports-q1-earnings-what-key-metrics-have-to-say">sales results on Monday</a>.
Charles Schwab reported a first-quarter 2024 adjusted net income decline of 17% Y/Y to $1.469 billion. Adjusted EPS fell 20% Y/Y to 74 cents, which came in line with the consensus. Revenue fell 7% to $4.74 billion, marginally beating the consensus of $4.71 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The company added 1 million new brokerage accounts to increase the total client base to 35.3 million (+3% Y/Y).
Walt Bettinger, Co-Chairman and CEO, said, &ldquo;Momentum across our array of wealth solutions continued through the first quarter. Led by record flows into our premier fee-based solution, Schwab Wealth Advisory&trade;, net inflows increased 60% versus the prior year period.&rdquo;
Charles Schwab shares gained 1.7% to close at $71.23 on Monday.
These analysts made changes to their price targets on Charles Schwab following earnings announcement.
<ul>
<li>JP Morgan raised the price target on Charles Schwab from $86 to $89. JP Morgan analyst Kenneth Worthington maintained an Overweight rating.</li>
<li>Barclays raised the price target on Charles Schwab from $74 to $75. Barclays analyst Benjamin Budish maintained an Equal-Weight rating.</li>
<li>B of A Securities boosted the price target on Charles Schwab from $68 to $70. B of A Securities analyst Craig Siegenthaler maintained an Underperform rating.</li>
<li>Piper Sandler raised the price target on Charles Schwab from $78 to $85. Piper Sandler analyst Patrick Moley maintained an Overweight rating.</li>
</ul>
&nbsp;
Read This Next: <a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields</a>

SCHW

These Analysts Raise Their Forecasts On Charles Schwab Following Upbeat Earnings

Oppenheimer analyst Kristen Owen maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNHI#NYSE">CNHI</a>) from Perform to Perform.

CNHI

Oppenheimer Maintains Perform on CNH Industrialto Perform

<a href="https://www.aboutamazon.com/news/entertainment/amazon-music-maestro-ai-playlist-generator">https://www.aboutamazon.com/news/entertainment/amazon-music-maestro-ai-playlist-generator</a>
Maestro is now available on all Amazon Music tiers in beta to a subset of U.S. customers on iOS and Android.
Today, Amazon Music announces a new feature that uses AI technology to make it easier and way more fun to build playlists you want, when you want. Meet Maestro: An AI playlist generator that helps you create any playlist you can think of—plus all the ones you can't. This feature is rolling out in beta to a small number of U.S. customers on all tiers of Amazon Music.
&nbsp;

AMZN

Amazon Music Launches Maestro, A New AI Playlist Generator, Maestro Now Available On All Amazon Music Tiers In Beta To A Subset Of U.S. Customers On iOS And Android

As the first-quarter (Q1) 2024 earnings season approaches, JPMorgan analyst Doug Anmuth, CFA, remains bullish on the Internet sector, citing fundamental drivers <a href="https://www.benzinga.com/tech">and company-specific performance</a>. 
Despite some turbulence, the internet sector has seen a weighted average increase of 23% in stock performance year to date. 
Anmuth&#8217;s key players to watch include Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and Uber Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NASDAQ">UBER</a>).
Also Read:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38247855/initial-wave-of-ai-software-growth-to-spur-microsoft-salesforce-palantir-mongodb-or"> &#8216;Initial Wave Of AI Software Growth&#8217; To Spur Microsoft, Salesforce, Palantir, MongoDB, Oracle, Snowflake, And Elastic, Says Analyst</a>
<h3 class="wp-block-heading">Amazon &#8211; Best Idea for 2024</h3>
Anmuth maintains Amazon as the top pick, calling it JPMorgan&#8217;s &#8220;Best Idea for 2024&#8221;. He emphasized its robust fundamentals and growth prospects. 
He anticipates accelerated growth in Amazon Web Services (AWS) throughout 2024, fueled by easing optimizations, new workload deployments, and early monetization of General Artificial Intelligence (GenAI). 
Additionally, strong growth in North America, improved international profitability, and disciplined cost management contribute to a multi-year Free Cash Flow (FCF) ramp. Investors are eyeing first-quarter net sales of $142B-$144B and AWS growth exceeding 15%, among other key metrics, indicating positive sentiment towards Amazon&#8217;s performance.
<h3 class="wp-block-heading">Meta &#8211; Room For Upside Potential</h3>
Meta&#8217;s solid first-quarter advertising checks and emergence as an AI leader in the ad sector bode well for the stock. Anmuth also shed light on the role of GenAI (General Artificial Intelligence) in investor discussions. While early benefits are primarily seen in coding efficiencies and cost savings, Meta stands out for its effective use of AI in enhancing its advertising capabilities.
Despite tougher year-over-year comparisons, Meta&#8217;s revenue is expected to meet or exceed guidance, with a mid-teens growth projection for the year.
With Meta trading at a modest 21x 2025E GAAP EPS, Anmuth sees room for upside potential, especially considering its position relative to other major companies.
On Monday, April 15, Meta won the dismissal of some claims in a dozen lawsuits accusing its CEO Mark Zuckerberg of concealing from the public that Facebook and Instagram <a href="https://www.benzinga.com/news/24/04/38263342/zuckerberg-dodges-a-bullet-judge-tosses-some-lawsuit-claims-against-meta-ceo-in-youth-harm-litigatio">were harmful to children</a>. 
<h3 class="wp-block-heading">Uber &#8211; Promising Three-Year Outlook</h3>
Uber continues to be a favored pick, with its resilience in demand, profitability initiatives, and promising three-year outlook. 
Although some key catalysts like GAAP profitability and S&amp;P 500 inclusion have passed, Anmuth believes Uber&#8217;s shares can still deliver through continued execution and earnings growth. 
The company&#8217;s shift towards absolute profit dollar growth rather than incremental margins aligns with its focus on profitability. Anmuth also sees upside potential in Uber&#8217;s $7 billion buyback plan running through 2026.
In summary, JPMorgan&#8217;s outlook for the Internet sector remains bullish, with Amazon, Meta, and Uber positioned as top picks. The integration of artificial intelligence, especially in Meta&#8217;s case, underscores its potential to drive future growth. 
However, cautious optimism is advised, considering potential challenges such as growth deceleration and high valuations in certain cases.
Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38252477/why-microsoft-alphabet-amazon-palantir-and-meta-could-rise-15-in-2024-according-to-">Why Microsoft, Alphabet, Amazon, Palantir, And Meta Could Rise 15% In 2024, According To Analyst</a>
Image: Shutterstock

Analyst Color

Long Ideas

Tech

UBER

Amazon, Meta, Uber Remain 'Top Overall Picks' At JPMorgan Ahead Of Q1 Earnings

WIIM

ITCI

Intra-Cellular shares are trading higher after the company announced Lumateperone 42 mg once daily as adjunctive therapy to antidepressants met its primary endpoint.

Oppenheimer analyst Kristen Owen maintains AGCO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGCO#NYSE">AGCO</a>) with a Outperform and raises the price target from $153 to $154.

AGCO

Oppenheimer Maintains Outperform on AGCO, Raises Price Target to $154

Macro Economic Events

Econ #s

Economics

USA Redbook (YoY) 4.9% Vs 5.4% Prior

UBS analyst Lloyd Walmsley maintains Snap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) with a Neutral and lowers the price target from $14 to $13.

SNAP

UBS Maintains Neutral on Snap, Lowers Price Target to $13

NCNA

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Nokia shares are trading higher in sympathy with Ericsson, which reported better-than-expected Q1 EPS results.

UBS analyst Erika Najarian maintains JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) with a Buy and lowers the price target from $226 to $219.

UBS Maintains Buy on JPMorgan Chase, Lowers Price Target to $219

Guidance

BofA CEO Says Replacement Of Lower Earning Assets Into Higher Yielding Assets Continues To Provide An Ongoing Benefit To Net Interest Income; Expects Q2 Net Interest Income To Reach $14B

AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>)&nbsp;<a target="_blank" href="https://od-prod-origin-astrazeneca-corporate.digital-astrazeneca.com/media-centre/press-releases/2024/imfinzi-plus-chemotherapy-doubled-overall-survival-rate-at-three-years-for-patients-with-advanced-biliary-tract-cancer-in-topaz-1-phase-iii-trial.html" rel="noreferrer noopener">released</a>&nbsp;updated exploratory results from the TOPAZ-1 Phase 3 trial of&nbsp;Imfinzi&nbsp;(durvalumab) in combination with standard-of-care chemotherapy for advanced biliary tract cancer (BTC).
The data showed that&nbsp;Imfinzi&nbsp;plus standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit in advanced biliary tract cancer patients at three years.
The company says the TOPAZ-1 results are the longest survival follow-up ever reported for a global, randomized Phase 3 trial in this setting.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38110994/new-hope-for-aggressive-lung-cancer-astrazenecas-imfinzi-shows-promising-results-in-phase-3-trial" rel="noreferrer noopener">New Hope for Aggressive Lung Cancer: AstraZeneca&#8217;s Imfinzi Shows Promising Results in Phase 3 Trial</a>.
At more than three years (median follow-up of 41.3 months), results showed&nbsp;that Imfinzi&nbsp;plus chemotherapy reduced the risk of death by 26% versus chemotherapy alone.&nbsp;
The median OS was 12.9 months for&nbsp;Imfinzi&nbsp;plus chemotherapy versus 11.3 months for chemotherapy alone.&nbsp;
More than twice as many patients on the&nbsp;Imfinzi-based regimen were alive at three years versus chemotherapy alone (14.6% versus 6.9%).
Do-Youn Oh, principal investigator in the trial, said: &#8220;The latest data from TOPAZ-1 show that twice as many patients with advanced biliary tract cancer were still alive at three years with durvalumab and chemotherapy, an especially meaningful advance in a setting where historically the prognosis has been poor.&#8221;
The TOPAZ-1 trial met the primary endpoint of OS in&nbsp;<a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2021/imfinzi-improved-survival-in-biliary-tract-cancer.html" rel="noreferrer noopener">October 2021</a>&nbsp;at a planned interim analysis, showing that the combination reduced the risk of death by 20% versus chemotherapy alone.
Median OS&nbsp;<a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2022/imfinzi-plus-chemotherapy-reduced-risk-of-death-by-20-in-1st-line-advanced-biliary-tract-cancer.html#!" rel="noreferrer noopener">was</a>&nbsp;12.8 months versus 11.5 for chemotherapy. An estimated 25% of patients were still alive at two years versus 10% for chemotherapy.
Results also showed a 25% reduction in the risk of disease progression or death with&nbsp;Imfinzi&nbsp;plus chemotherapy.
Median progression-free survival (PFS) was 7.2 months for the combination versus 5.7 for chemotherapy.&nbsp;
Patients treated with&nbsp;Imfinzi&nbsp;plus chemotherapy achieved an objective response rate (ORR) of 26.7% versus an ORR of 18.7% for patients treated with chemotherapy alone.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38201849/astrazeneca-hikes-annual-dividend-by-7-just-before-vote-on-its-ceos-pay-package-boost" rel="noreferrer noopener">AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO&#8217;s Pay Package Boost</a>.
Price Action: AZN shares are down 0.01% at $68.72 during the premarket session on the last check Tuesday.
Photo via Wikimedia Commons

Biotech

Large Cap

AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows

M&amp;T Bank Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtb#NYSE">MTB</a>) reported in-line <a href="https://www.benzinga.com/news/earnings/24/04/38246924/why-m-t-bank-shares-are-trading-higher-today">first-quarter earnings on Monday</a>.
Revenue of $2.260 billion, slightly missing the consensus of $2.263 billion. Net income of $531 million came below $702 million a year ago. EPS was $3.09, which came in line with the consensus, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
M&amp;T held total assets of $211.5 billion as of March 31, 2024. Loans and leases, net of unearned discount, were $133.8 billion. The CET1 capital ratio was estimated at 11.07% as of March 31, 2024.
Daryl N. Bible, M&amp;T&rsquo;s Chief Financial Officer, said,&ldquo;We are off to a solid start in 2024 as we were able to grow certain sectors of our commercial and consumer loan portfolios, while continuing to shrink our commercial real estate exposure. Expenses were prudently managed in the recent quarter and our selective approach to allocating resources to our strategic priorities with utmost care has not wavered.&rdquo;
M&amp;T Bank shares gained 4.6% to close at $140.94 on Monday.
These analysts made changes to their price targets on M&amp;T Bank following earnings announcement.
<ul>
<li>B of A Securities raised the price target on M&amp;T Bank from $157 to $160. B of A Securities analyst Ebrahim Poonawala maintained a Buy rating.</li>
<li>Wells Fargo raised the price target on M&amp;T Bank from $145 to $150. Wells Fargo analyst Mike Mayo maintained an Equal-Weight rating.</li>
<li>RBC Capital analyst Gerard Cassidy, meanwhile, reiterated M&amp;T Bank with an Outperform and maintained a $160 price target.</li>
</ul>
&nbsp;
Read This Next: <a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields</a>

M&T Bank Analysts Boost Their Forecasts After Q1 Results

PALI

Palisade Bio shares are trading higher after the company announced the completion of analysis evaluating ex-vivo bioactivation of PALI-2108.

Oppenheimer analyst Leland Gershell upgrades Avalo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTX#NASDAQ">AVTX</a>) from Perform to Outperform and announces $35 price target.

Upgrades

AVTX

Oppenheimer Upgrades Avalo Therapeutics to Outperform, Announces $35 Price Target

UBS analyst Lloyd Walmsley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $530 to $610.

UBS Maintains Buy on Meta Platforms, Raises Price Target to $610

PNC Financial Services Group Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) shares are trading lower after it reported&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/n38265700/pnc-reports-first-quarter-2024-net-income-of-1-3-billion-3-10-diluted-eps-or-3-36-excluding-a-130-" rel="noreferrer noopener">first-quarter FY24 results</a>.
The bank reported a revenue decline of 8% Y/Y to $5.15 billion, missing the consensus of $5.19 billion. Revenue declined Y/Y due to lower net interest income and noninterest income.&nbsp;
Net interest income fell 9% Y/Y to $3.26 billion, with a net interest margin declining to 2.57% from 2.84% prior year quarter.
Noninterest income decreased 7% Y/Y to $1.88 billion due to a decline in capital markets and advisory revenue, fee income, and residential and commercial mortgage businesses.
Average loans fell 2% Y/Y, and average deposits decreased 4% Y/Y in the first quarter. Adjusted EPS of $3.36 came <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">above the consensus of $3.02</a>.
The company reported a provision for credit losses of $155 million in the quarter (vs. $235 million a year ago), reflecting portfolio activity and improved macroeconomic factors. CET1 capital ratio stood at 10.1% vs. 9.2% in the prior year quarter. 
Dividend: On April 3, PNC&#8217;s board of directors declared a quarterly cash dividend per share of $1.55, payable on May 6, 2024, to shareholders of&nbsp;<a target="_blank" href="https://www.benzinga.com//node/38072433" rel="noreferrer noopener">record as of April 15, 2024.</a>
PNC returned $0.8 billion of capital to shareholders, comprising share repurchases over $0.1 billion in the quarter.
Bill Demchak, Chairman and CEO, said, &#8220;PNC delivered solid first quarter results generating net income of $1.3 billion which included an additional $130 million pre-tax FDIC special assessment. During the quarter, we grew customers, reduced expenses, increased spot deposits, maintained stable credit quality and continued to build upon our strong liquidity and capital positions.&#8221;
Investors can gain exposure to the stock via&nbsp;IShares U.S. Regional Banks ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAT#NYSE">IAT</a>) and&nbsp;Invesco Exchange-Traded Fund Trust II Invesco S&amp;P Ultra Dividend Revenue ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDIV#NYSE">RDIV</a>).
Guidance: For FY24, PNC continues to <a href="https://d1io3yog0oux5.cloudfront.net/_4dd30b1093d2402ec5f5c10de4b909bf/pnc/db/2250/21495/presentation/1Q24+Earnings+Slides_Final.pdf">expect </a>revenue to be stable to down 2%, with net interest income declining 4% – 5% Y/Y.
The bank expects revenues to be stable and net interest income to be&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">down 1% on a sequential basis in the second quarter of FY24</a>.
Price Action: PNC shares are down 1.88% at $146.75 premarket on the last check Tuesday.
Photo via Wikimedia Commons

Equities

Dividends

Buybacks

iShares Dow Jones US Regional Banks Index Fund

RDIV

What's Going On With PNC Financial Shares Today?

Passage Bio Inc (PASG) has risen Wednesday morning, with the stock rising 3.85% in pre-market trading to 1.62. PASG's short-term technical score of 68 indicates that the stock has traded more bullishly over the last month than 68% of stocks on the market. In the Biotechnology industry, which ranks 85 out of 146 industries,

Premarket Mover: Passage Bio Inc (PASG) Up 3.85%

Passage Bio (PASG) has shared an announcement. Kathleen Borthwick has been appointed as the Chief Financial Officer of a company, effective March 1...

Passage Bio Welcomes Kathleen Borthwick as New CFO

Passage Bio GAAP EPS of -$1.86 beats by $0.04

Passage Bio files for $200M mixed shelf offering

Passage Bio, Inc. (PASG) has disclosed a new risk, in the Innovation / R&D category. Passage Bio, Inc. faces significant business risk as their pro...

New Innovation / R&D Risk for Passage Bio, Inc. – What's the Latest?

The market has been high on Passage Bio Inc (PASG)  stock recently. PASG gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Passage Bio Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PASG!See Full PASG ReportWhat is Stock Sentiment?Sentiment use

Should You Buy Passage Bio Inc (PASG) Stock After it Has Risen 2.56% in a Week?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Passage Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pasg-stock-quote/">PASG</a>) just reported results for the fourth quarter of 2023.<ul><li>Passage Bio reported earnings per share of -30 cents. This was above the analyst estimate for EPS of -40 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/pasg-stock-earnings-passage-bio-for-q4-of-2023/">PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023

Passage Bio Inc (PASG) stock is higher by 14.18% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Passage Bio Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on PASG!See Full PASG ReportWhat is Stock Sentiment?Sentiment is a very

What is the Market's View on Passage Bio Inc (PASG) Stock's Price and Volume Trends Tuesday?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Quanterix (QTRX – Research Report), Passage Bio (PAS...

Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Wave Life Sciences (WVE – Research Report), Passage ...

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Passage Bio Stock (NASDAQ:PASG), Trade Ideas